Citius Oncology (NASDAQ:CTOR) versus Structure Therapeutics (NASDAQ:GPCR) Financial Analysis

Citius Oncology (NASDAQ:CTOR) and Structure Therapeutics (NASDAQ:GPCR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, institutional ownership, valuation and profitability.

Profitability

This table compares Citius Oncology and Structure Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Citius Oncology	N/A	-51.93%	-22.17%
Structure Therapeutics	N/A	-21.31%	-20.34%

Earnings and Valuation

This table compares Citius Oncology and Structure Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Oncology	N/A	N/A	N/A	N/A	N/A
Structure Therapeutics	N/A	N/A	-$122.53 million	($1.05)	-27.31

Institutional and Insider Ownership

70.5% of Citius Oncology shares are owned by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are owned by institutional investors. 6.7% of Citius Oncology shares are owned by insiders. Comparatively, 5.6% of Structure Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations for Citius Oncology and Structure Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Oncology	1	0	2	0	2.33
Structure Therapeutics	1	0	7	1	2.89

Citius Oncology presently has a consensus target price of $6.00, indicating a potential upside of 220.86%. Structure Therapeutics has a consensus target price of $68.67, indicating a potential upside of 139.42%. Given Citius Oncology’s higher possible upside, equities analysts clearly believe Citius Oncology is more favorable than Structure Therapeutics.

Volatility and Risk

Citius Oncology has a beta of 2.92, meaning that its stock price is 192% more volatile than the S&P 500. Comparatively, Structure Therapeutics has a beta of -1.65, meaning that its stock price is 265% less volatile than the S&P 500.

Summary

Structure Therapeutics beats Citius Oncology on 6 of the 9 factors compared between the two stocks.

About Citius Oncology

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

About Structure Therapeutics

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.